| HOME >> BIOLOGY >> TECHNOLOGY |
Industry Participants 28
Classification of Pharmaceutical Companies Based on their
Existing Capabilities in Global Biosimilars Market 29
9. PRODUCT APPROVALS 30
DRL Launches Cresp® in India 30
Hospira Receives EC Approval for Nivestim™ 30
Reliance Life Sciences to Introduce Erythropoietin in Europe 30
Sandoz Introduces Zarzio® Filgrastim Preparation 30
Shasun Chemicals & Drugs Introduces Streptokinase 31
Sandoz Obtains FDA Approval for Omnitrope® Pen 10 with Liquid
Cartridge 31
Sandoz Launches Somatropin in Japan 31
Sandoz Obtains European Approval for Third Biosimilar, Filgrastim 32
Ratiopharm Introduces Neupogen Biosimilar in French Market 32
Biocon Launches Basalog in India 32
Reliance Life Sciences to Launch Three More Biosimilars in 2010 32
Wockhardt Launches Glaritus Insulin In India 33
Teva Pharmaceutical Obtains Marketing Authorization from EU
for TevaGrastim® 33
Ratiopharm Obtains Approval from EMEA for Biosimilar Ratiograstim 33
Hospira Introduces Retacrit in UK 34
Retacrit® Demonstrates Safety and Efficacy in Chemotherapy
Induced Anaemia 34
Sandoz Collaborates with Gambro for Binocrit 34
ABRPL to Launch Eight Biosimilars in India 34
Sandoz Receives EC Approval to Introduce Epoetin Alfa Biosimilar 35
Sandoz Bags EC Marketing Approval for Omnitrope 35
Biopartners Bags EU Marketing Approval for Valtropin 35
Omnitrope Receives US FDA Approval 35
10. CORPORATE INITIATIVES IN THE GLOBAL BIOSIMILARS SPACE 36
Sandoz Commences Phase II Clinical Trial for Biosimilar
Version of Rituximab 36
Cipla to Acquire Minority Stake in Bio Mabs and Mab Pharm 36
Biocon Signs Agreement with Pfizer 36
Actavis Group to Purchase Majority Stake in Biopartners from
Bioton 37
Sand
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |